Related Experiment Video
Updated: Dec 24, 2025

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid
Published on: April 7, 2023
The Brain-Heart Axis: Alzheimer's, Diabetes, and Hypertension
Andrew S Riching1,2, Jennifer L Major1,2, Pilar Londono3
1Department of Medicine, Division of Cardiology, University of Colorado Anschutz Medical Campus, Aurora, Colorado 80045, United States.
Insights
Alzheimer's disease (AD) may be a form of Type III Diabetes (T3D). Treatments for Type II Diabetes (T2D), like metformin, show promise for improving cognitive function and preventing AD.
Area of Science:
- Neuroscience
- Endocrinology
- Cardiovascular Science
Background:
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder with limited treatment options.
- Current AD drug development targeting brain pathologies (plaques and tangles) has faced significant clinical trial failures.
- Emerging research suggests a strong link between AD and Type II Diabetes (T2D), proposing AD as a brain-specific manifestation termed Type III Diabetes (T3D).
Purpose of the Study:
- To review current research and clinical trials for Alzheimer's disease.
- To explore the potential of Type II Diabetes (T2D) treatments for Alzheimer's disease (AD).
- To highlight the systemic nature of AD, involving the brain-heart axis and its regulation of hypertension and diabetes.
Main Methods:
- Literature review of past and ongoing research in Alzheimer's disease (AD).
- Analysis of studies investigating the link between Type II Diabetes (T2D) and neurodegenerative disorders.
- Examination of research on the brain-heart axis, hypertension, and diabetes in relation to cognitive function.
Main Results:
- Type II Diabetes (T2D) medications, such as metformin, demonstrate potential in enhancing cognitive function and preventing Alzheimer's disease (AD) in diabetic individuals.
- The brain and cardiovascular system communicate via the vasculature, influencing fluid and nutrient balance.
- The brain-heart axis plays a role in regulating hypertension and diabetes, both critical factors affecting cognitive health.
Conclusions:
- Alzheimer's disease (AD) is increasingly viewed as a complex, systemic disorder rather than solely a brain-centric condition.
- Treatments targeting Type II Diabetes (T2D) show promise for managing Alzheimer's disease (AD) symptoms and progression.
- Comprehensive therapeutic strategies addressing systemic factors, including the brain-heart axis, are crucial for effective Alzheimer's disease (AD) prevention and treatment.
Abstract:
Alzheimer's disease (AD) is a debilitating neurodegenerative disorder affecting millions worldwide. Currently, there are only four approved treatments for AD, which improve symptoms modestly. AD is believed to be caused by the formation of intercellular plaques and intracellular tangles in the brain, but thus far all new drugs which target these pathologies have failed clinical trials. New research highlights the link between AD and Type II Diabetes (T2D), and some believe that AD is actually a brain specific form of it termed Type III Diabetes (T3D). Drugs which are currently approved for the treatment of T2D, such as metformin, have shown promising results in improving cognitive function and even preventing the development of AD in diabetic patients. Recent studies shed light on the relationship between the brain and cardiovascular system in which the brain and heart communicate with one another via the vasculature to regulate fluid and nutrient homeostasis. This line of research reveals how the brain-heart axis regulates hypertension and diabetes, both of which can impact cognitive function. In this review we survey past and ongoing research and clinical trials for AD, and argue that AD is a complex and systemic disorder which requires comprehensive approaches beyond the brain for effective prevention and/or treatment.
Related Concept Videos
Psychoneuroimmunology: Diabetes and Cancer
Hypertension II: Pathophysiology
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Disorders of the Autonomic Nervous System
Raynaud's disease, also known as Raynaud's...
Heart Failure II: Pathophysiology
Coronary Artery Disease I: Introduction

